MedPath

The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients

Not Applicable
Completed
Conditions
Irritable Bowel Syndrome
Hypersensitivity
Interventions
Dietary Supplement: multispecies probiotic (Ecologic 801)
Dietary Supplement: Placebo
Registration Number
NCT00702026
Lead Sponsor
Maastricht University Medical Center
Brief Summary

The purpose of this study is to determine whether a specifically designed multispecies probiotic decreases visceral hypersensitivity in IBS-patient (defined by an increased pain tolerance threshold). Moreover, the effect on general symptom scores and inflammatory and microbiological parameters will be studied.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Clinical diagnosis of IBS according to the Rome III criteria
  • Increased visceral perception according to barostat measurements, defined as a pain tolerance threshold at smaller than or equal to 23 mmHg
  • Age between 18 and 65 years
  • BMI between 18.5 and 30 kg/m2
Exclusion Criteria
  • Known gastro-intestinal diseases
  • Major abdominal surgery
  • Previous radiotherapy, chemotherapy
  • Clinical significant systemic diseases
  • Critically ill patients or patients suffering from severe acute pancreatitis
  • Patients with organs failure
  • Patients receiving enteral feeding
  • Excessive alcohol intake (greater than 15 consumptions per week)
  • (planned) pregnancy or lactation
  • Use of pre-, probiotics in the month before and during the study
  • Use of antibiotics in the two months before and during the study
  • Use of anti-diarrhoea medication, anti-laxatives or anti-acid medication in the two weeks before and during the study
  • Use of anti depressives (especially SSRI's) in the month before and during the study
  • Use of other medication if less then one month on stable dosage

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1multispecies probiotic (Ecologic 801)-
2Placebo-
Primary Outcome Measures
NameTimeMethod
Pain tolerance thresholdt=0 and t=6 weeks
VAS score for pain at pressure step 29 mmHgt=0 and t=6 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Hospital Maastricht

🇳🇱

Maastricht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath